Ionis Pharmaceuticals IONS Long Term Obligations Noncurrent
Discontinued — last reported Q4 '25
Long Term Obligations Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:LongTermObligationsNoncurrent.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's long term obligations noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's long term obligations noncurrent?
- Ionis Pharmaceuticals (IONS) reported long term obligations noncurrent of $2.16B in Q4 2025.
- What is the long-term trend for Ionis Pharmaceuticals's long term obligations noncurrent?
- Over 2 years (2020 to 2025), Ionis Pharmaceuticals's long term obligations noncurrent has grown at a 860.8% compound annual growth rate (CAGR), from $23.41M to $2.16B.
- What does long term obligations noncurrent mean?
- Long-term financial obligations that are not classified as debt or leases.
- How do you interpret long term obligations noncurrent?
- An increase may indicate rising long-term liabilities or changes in accounting estimates, while a decrease suggests the settlement or reduction of these obligations.
- How does long term obligations noncurrent compare across companies?
- Varies significantly by industry; biotech firms often have lower levels compared to capital-intensive manufacturing firms.